AstraZeneca Pharma India reported a 23% year-on-year decline in net profit for the March quarter at ₹44.8 crore, compared with ₹58.2 crore in the corresponding period last year, as lower operating margins weighed on profitability despite robust revenue growth.
Revenue from operations rose 20.4% year-on-year to ₹578.6 crore in Q4FY26 from ₹480.4 crore a year earlier, supported by continued momentum across key therapy segments.
EBITDA declined 29.4% to ₹60.9 crore against ₹86.2 crore in the year-ago quarter, while EBITDA margin contracted sharply to 10.5% from 17.9%.
For FY26, the company reported total revenue from operations of ₹2,275.6 crore, driven by sustained growth in Oncology and Biopharmaceuticals, along with progress in the Rare Disease segment. During the year, the company secured 11 new regulatory approvals for medicines and indications in India.
Bhavana Agrawal, Chief Financial Officer and Director, said FY26 was a year of “strong and consistent growth” supported by the company’s science-led portfolio and disciplined execution.
Managing Director Praveen Rao Akkinepally said the company remains focused on accelerating access to innovative medicines and addressing unmet medical needs through science-led innovation.
The board has recommended a dividend of ₹36 per equity share of face value ₹2 each for FY26, subject to shareholder approval.
Separately, the board approved the re-appointment of Shilpa Divekar Nirula as Non-Executive Independent Director for a second consecutive term of five years beginning December 29, 2026, subject to shareholders’ approval.
Ahead of the earning announcements, shares of AstraZeneca Pharma India closed 2.56% higher at ₹9,025 on the NSE.
Also Read: IAN Group invests ₹625 crore in 50 deep-tech startups, ramps up AI focus
